deferoxamine has been researched along with Hyperparathyroidism in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Their prevention relies on adequate treatment of tapwater and definitive exclusion of long term administration of aluminum phosphate binders." | 2.41 | [Renal osteodystrophy (3); its treatment in dialysis patients]. ( Arsenescu, I; Benamar, L; el Esper, N; Fournier, A; Ghitu, S; Morinière, P; Oprisiu, R; Said, S; Tataru Albu, A, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghitu, S | 1 |
| Oprisiu, R | 1 |
| Benamar, L | 1 |
| Said, S | 1 |
| Tataru Albu, A | 1 |
| Arsenescu, I | 1 |
| el Esper, N | 1 |
| Morinière, P | 1 |
| Fournier, A | 1 |
| McCarthy, JT | 2 |
| Milliner, DS | 1 |
| Johnson, WJ | 1 |
| Almirall, J | 1 |
| Campistol, JM | 1 |
| Torras, A | 1 |
| Revert, L | 1 |
| Terao, N | 1 |
| Suzuki, M | 1 |
| Homma, S | 1 |
| Asano, Y | 1 |
| Hosoda, S | 1 |
| Furuse, M | 1 |
| Charhon, SA | 1 |
| Chavassieux, PM | 1 |
| Chapuy, MC | 1 |
| Traeger, J | 1 |
| Meunier, PJ | 1 |
| Kurtz, SB | 1 |
| McCall, JT | 1 |
1 review available for deferoxamine and Hyperparathyroidism
| Article | Year |
|---|---|
[Renal osteodystrophy (3); its treatment in dialysis patients].
Topics: Aluminum; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Def | 2000 |
5 other studies available for deferoxamine and Hyperparathyroidism
| Article | Year |
|---|---|
Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
Topics: Aluminum; Bone and Bones; Deferoxamine; Female; Humans; Hyperparathyroidism; Iron; Long-Term Care; M | 1990 |
Hyperparathyroidism after aluminum depletion.
Topics: Aluminum; Deferoxamine; Humans; Hyperparathyroidism; Parathyroid Hormone; Renal Dialysis | 1990 |
Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
Topics: Adult; Aluminum; Bone Diseases; Deferoxamine; Female; Fractures, Spontaneous; Humans; Hyperparathyro | 1988 |
High bone turnover associated with an aluminum-induced impairment of bone mineralization.
Topics: Aluminum; Biopsy; Bone and Bones; Bone Diseases, Metabolic; Deferoxamine; Humans; Hyperparathyroidis | 1986 |
Elevated bone aluminum content in dialysis patients without osteomalacia.
Topics: Adult; Aluminum; Biopsy; Bone and Bones; Deferoxamine; Glomerulonephritis; Histocytochemistry; Human | 1985 |